The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kernan, N. A.
Right arrow Articles by Dupont, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kernan, N. A.
Right arrow Articles by Dupont, B.

The Journal of Immunology, Vol 133, Issue 1 137-146, Copyright © 1984 by American Association of Immunologists

ARTICLES

Specific inhibition of in vitro lymphocyte transformation by an anti- pan T cell (gp67) ricin A chain immunotoxin

NA Kernan, RW Knowles, MJ Burns, HE Broxmeyer, L Lu, HM Lee, RT Kawahata, PJ Scannon and B Dupont

The toxin A chain of ricin has been conjugated by a disulfide bond to a murine monoclonal antibody that recognizes the gp67kD antigen present on 95% of peripheral T lymphocytes. The immunotoxin retains both functions of its component parts: it binds to human peripheral blood lymphocytes, and it inhibits protein synthesis in a cellfree reticulocyte system. The immunotoxin has been evaluated for its ability to inhibit in vitro T lymphocyte transformation. In the presence of 20 mM NH4Cl, the immunotoxin decreases lymphocyte proliferation in response to phytohemagglutinin to less than 8% of untreated controls. The proliferative response in mixed lymphocyte culture and the development of allocytotoxic T cells is also dramatically inhibited by this immunotoxin. Monoclonal antibody alone does not inhibit these responses. Specificity of the immunotoxin has been established: the effect of the immunotoxin can be blocked by unconjugated monoclonal antibody, but not by a control monoclonal antibody that recognizes another T lymphocyte differentiation antigen or by a control monoclonal antibody that does not recognize human peripheral blood leukocytes. Treatment of human bone marrow cells with the immunotoxin preserves hematopoietic progenitor cells, as measured by granulocyte-macrophage, erythroid, and multipotential hematopoietic progenitor cell assays. These results indicate that an anti-pan T lymphocyte-ricin A chain immunotoxin is an effective agent against immunocompetent T lymphocytes in vitro, and may be an effective agent for use in clinical bone marrow transplantation.


This article has been cited by other articles:


Home page
 BloodHome page
P. J. Henslee-Downey, S. H. Abhyankar, R. S. Parrish, A. R. Pati, K. T. Godder, W. J. Neglia, K. S. Goon-Johnson, S. S. Geier, C. G. Lee, and A. P. Gee
Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow Transplant
Blood, May 15, 1997; 89(10): 3864 - 3872.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Better, S. L. Bernhard, R. E. Williams, S. D. Leigh, R. J. Bauer, A. H. C. Kung, S. F. Carroll, and D. M. Fishwild
T Cell-targeted Immunofusion Proteins from Escherichia coli
J. Biol. Chem., June 23, 1995; 270(25): 14951 - 14957.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1984 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1984 by The American Association of Immunologists, Inc. All rights reserved.